NeuroTherapia

Executive Summary

NeuroTherapia is a clinical-stage biotechnology company developing novel small molecule therapeutics that target neuroinflammation via cannabinoid type 2 (CB2) receptor agonism. Based in Cleveland, Ohio, the company's lead candidate, NTRX-07, is being evaluated for Alzheimer's disease and neuropathic pain. By inhibiting microglial activation, NTRX-07 aims to modulate the immune response in the central nervous system, potentially slowing disease progression. The company has completed preclinical studies and is advancing through Phase 1 clinical trials. NeuroTherapia's approach is differentiated by its focus on CB2 receptors, which are primarily expressed on immune cells, potentially offering a favorable safety profile compared to CB1-targeting cannabinoids. The company is privately held and has not disclosed total funding, but its progress suggests it is a lean operation with a focused pipeline. While still early-stage, the scientific rationale and unmet need in neurodegenerative diseases position NeuroTherapia as an intriguing opportunity for investors seeking exposure to neuroinflammation-targeted therapies.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for NTRX-07 in Alzheimer's disease25% success
• Q1 2027Initiation of Phase 2 trial for NTRX-07 in neuropathic pain35% success
• Q4 2026Announcement of strategic partnership or financing round30% success